Lanean...
Resolution of Pembrolizumab‐Associated Steroid‐Refractory Lichenoid Dermatitis with Cyclosporine
Checkpoint inhibitors such as pembrolizumab, an anti‐PD‐1 monoclonal antibody, are a promising new category of oncological therapeutics, associated with a higher risk of immune‐related adverse events including dermatological, autoimmune and endocrine sequelae. Here, we present a case of a woman 76 y...
Gorde:
| Argitaratua izan da: | Oncologist |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley & Sons, Inc.
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6519769/ https://ncbi.nlm.nih.gov/pubmed/30617087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0531 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|